Home · Health · Aug 30 archive
FDA Approves Rusfertide for Rare Blood Cancer
Developing
In Short: The FDA has approved rusfertide, developed by Protagonist Therapeutics, to treat polycythemia vera, a chronic condition where the body overproduces red blood cells.
The FDA has approved rusfertide, developed by the biotech company Protagonist Therapeutics, for the treatment of polycythemia vera, a rare blood cancer. This approval allows for the administration of Mimrylo, a weekly injection, to patients suffering from this condition.
Polycythemia vera leads to an overproduction of red blood cells, causing the blood to thicken and increasing the risk of life-threatening heart attacks, strokes, and blood clots.
What's confirmed
What's still developing
- The drug, called rusfertide, was developed by the biotech company Protagonist Therapeutics.
- Administered via a weekly injection, Mimrylo was cleared to treat polycythemia vera, a chronic blood cancer in which overproduction of red blood cells thickens a patient’s blood, resulting in higher risk for…
Sources
- STATlink